Objectives: The aim of this study was to investigate Polish clinical isolates of Streptococcus pyogenes collected during a 7 year period using phenotypic and genotypic techniques.
Introduction
Since the 1940s, penicillin has been the treatment of choice for Streptococcus pyogenes infections, whereas erythromycin and clindamycin are usually recommended as alternative antibiotics. The first erythromycin-resistant strain of Streptococcus was described in 1959 in the UK and since then in many countries. 1 Whereas data regarding the prevalence of S. pyogenes resistance to macrolides have been reported worldwide, the problem in Poland has remained unstudied until now.
The aim of this study was to investigate the susceptibility patterns of Polish clinical isolates of S. pyogenes, with particular emphasis on macrolide resistance and the underlying genetic determinants of this resistance. The clonal structure of macrolide-resistant isolates was studied by PFGE of Sma I-restricted bacterial DNA as well as multilocus sequence typing (MLST) and emm typing of selected strains.
Materials and methods

Bacterial isolates
Eight hundred and sixteen isolates of S. pyogenes were collected during 1996-2002 at 33 medical centres in Poland. The number of strains collected in the periods 1996 -1997, 1998 -1999 and 2000-2002 were 266, 258 and 292, respectively. The isolates were recovered from throat swabs (n = 438), pus (n = 331), blood (n = 17), sputum (n = 8) and other sources (n = 22). Of these, 361 isolates were obtained from children and 455 from adult patients. S. pyogenes were identified by standard procedure using a commercially available agglutination kit (Streptex, Murex Biotech Limited, UK).
Determination of MICs and erythromycin resistance phenotypes
MICs were determined according to the NCCLS guidelines 2 by the standard microdilution method. Streptococcus pneumoniae ATCC 49619 was used as a quality control strain. The MIC breakpoints were interpreted according to the NCCLS.
2 Breakpoints for spiramycin were those proposed by the French Society for Microbiology.
3 For all strains, susceptibility to the following antimicrobials was tested: penicillin G, erythromycin, tetracycline (Sigma-Aldrich, Steinheim, Germany) and clindamycin (Pharmacia Upjohn, Inc., Kalamazoo, MI, USA). Erythromycin-resistant strains (MIC> _ 1 mg/L) were additionally tested for susceptibility to clarithromycin (Abbott Laboratories Chicago, IL, USA), roxithromycin (Roussel Uclaf, Paris, France), azithromycin (Pliva Kraków, Poland), spiramycin, (Rhone-Poulenc Rorer, Collegeville, PA, USA), telithromycin, quinupristin/dalfopristin (Aventis Pharma, Romainville, France), linezolid (Pharmacia & Upjohn, Inc., Kalamazoo, MI, USA) and moxifloxacin (Bayer AG, Wuppertal, Germany). All erythromycin-resistant isolates were assigned to their particular phenotypes, such as inducible MLS B (iMLS B ), constitutive MLS B (cMLS B ) and efflux-mediated resistance (M phenotype) on the basis of the double erythromycin -clindamycin disc test. 4 Detection of erythromycin resistance genes PCR detection of erm(B) and mef(A) genes was carried out as reported by Sutcliffe et al.
5
; the erm(TR) gene was detected with primers described by Kataja et al. 4 
PFGE analysis, MLST and emm typing
Chromosomal DNA of erythromycin-resistant isolates was digested with Sma I restriction enzyme (MBI Fermentas, Lithuania) and analysed by PFGE, as described elsewhere. 6 PFGE patterns were analysed according to the criteria proposed by Tenover et al.
7
MLST was performed on representatives of all PFGE types and subtypes, following the method established by Enright et al.
8
; particular allele numbers and sequence types (STs) were identified using the MLST database (www.mlst.net). emm types for the isolates characterized by MLST were determined according to the recommendations of the Division of Bacterial and Mycotic Diseases, Centers for Disease Control and Prevention, S. pyogenes emm sequence database (http://www.cdc.gov/ncidod/biotech/strep/ doc.htm).
Statistical analysis
Comparison of frequencies between groups was performed using x 2 analysis. A P value of <0.05 was considered statistically significant.
Results and discussion
All 816 clinical S. pyogenes isolates examined in our study were highly susceptible to penicillin G. The highest rate of resistance was found for tetracycline (43%) and the rate was higher among isolates from adults (62%). These results are similar to those observed by Jasir et al. 9 in Iran and once again indicate that tetracycline is not an appropriate choice for empirical therapy of S. pyogenes infections.
Several European countries reported an increase in erythromycin resistance in S. pyogenes at the beginning of the 1990s. 1 In our study, altogether 98 isolates (12.0%) were resistant to erythromycin. The proportion of these isolates in adults was higher (64%) than in children. The frequency of erythromycin-resistant strains showed a rising trend over the years, from 1.8% in 1996-1997, to 12% in 1998-1999, to 25.1% in 2000-2002. The P values between 1.8% and 12%, 12% and 25.1% and 1.8% and 25.1% were 0.001, 0.01 and 0.001, respectively, showing a statistical significance. All erythromycin-susceptible isolates were also susceptible to clindamycin (MICs, 0.003-0.25 mg/L). Among the 98 erythromycin-resistant isolates, 65 (66.6%) exhibited the iMLS B and 28 (28.2%) the cMLS B phenotype (Table 1 ). All the iMLS B phenotypes harboured the erm(TR) gene. In the more diverse group of cMLS B isolates, 20 (71.4%) and eight (28.6%) contained erm(TR) and erm(B), respectively. Overall, 85 isolates (86.7%) showed the presence of erm(TR). Such a high prevalence of the erm(TR) isolate among macrolide-resistant S. pyogenes in Poland is unusual compared with other countries. 4,10 -12 The M phenotype occurred in only five isolates (5.1%) and all possessed the mef(A) gene. Similarly, a low prevalence of the M phenotype (10%) was found in a study conducted in Berlin. 10 However, other investigators have demonstrated that the M phenotype accounted for >80%. 1 In our study, all iMLS B and M-phenotype isolates were susceptible to clindamycin and telithromycin. In contrast, all cMLS B isolates were resistant to clindamycin. In the case of ketolides, we found eight (8.1%) erm(B)-positive cMLS B isolates that were resistant to telithromycin ( Table 1 ). The data presented here, which confirmed that the isolates with the erm(B) gene were resistant to telithromycin, are in accordance with studies from Spain 11 and from other European countries. 12 In the present study, we determined the susceptibilities of macrolide-resistant S. pyogenes to antibiotics belonging to various groups. All tested isolates were fully susceptibility to linezolid, moxifloxacin and quinupristin/dalfopristin. These agents demonstrated good in vitro activity independent of the macrolide resistance phenotype present (Table 1) . Hence these antibiotics could be used as alternatives for the treatment of S. pyogenes infections in selected cases.
Until now, no data have been available on the genetic diversity of Polish S. pyogenes isolates resistant to macrolides. PFGE analysis was performed on 95 of the 98 macrolide-resistant strains (three M-phenotype isolates were not typeable). Altogether, 13 different PFGE patterns, designated A-N, were discerned among the isolates (Table 2) , with two predominant PFGE profiles A (n = 41) and B (n = 25). Among the type A and B isolates, five (A1 -A5) and four (B1 -B4) PFGE subtypes were found, respectively. Whereas all the 41 isolates of the PFGE subtypes A1-A51 showed the iMLS B phenotype, six isolates of the PFGE type B1 had the cMLS B phenotype and 19 (B1-B4) were iMLS B . All the isolates belonging to the A and B clones harboured the erm(TR) gene (Table 2 ) and were resistant to tetracycline. Thirty-three (80%) isolates of the A type were recovered from wounds, whereas the majority of the B type (76%) were from throat samples. Overall, the isolates belonging to clones A and B accounted for almost 90% of isolates of the iMLS B phenotype. It can be concluded, therefore, that S. pyogenes of the iMLS B phenotype in Poland are highly clonal. In contrast, the cMLS B isolates showed a polyclonal nature (six different PFGE types).
The representatives of all PFGE types and subtypes were further subjected to MLST analysis and emm typing, resulting in 10 different STs and eight emm types ( Table 2 ). The majority of STs found in this study, in particular: ST63 (characteristic of all the subtype B1 -B4 isolates as well as isolates of types F, G, H); ST28 (subtypes C1-C3); ST36 (subtypes D1-D3 and three nontypeable isolates); ST46 (type K) and ST52 (type N) have been previously found among erythromycin-resistant S. pyogenes in Germany. 13 In contrast, the main clone of PFGE subtypes A1 -5 represented a novel ST367 (emm type 44/61). This clone, in which resistance developed presumably locally, constitutes a single local variant of ST25, isolated in the 1950s and 1970 in Northern and Central America. 8 Erythromycin and tetracycline resistance may, in this case, represent a strong selective advantage, which drives successful spread of the new clone under antibiotic pressure.
In summary, the present study demonstrates the alarming increase in macrolide resistance in S. pyogenes in Poland over 
